Acotec DCB Post Market Clinical Follow-up

Who May Qualify: - 1\. Patient is ≥ 18 years old at the time of consent. - 2\. Significant stenosis (≥70%) or occlusions of de-novo or restenotic lesion(s) located in iliac, superficial femoral, popliteal and/or infra-popliteal arteries suitable for angioplasty per operator visual assessment. - 3\. Lesion(s) can be treated with available AcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") DCB device per current IFU. - 4\. Subject has provided written willing to sign a consent form prior to participation in the PMCF, understands the purpose of this PMCF and agrees to comply with all protocol-specified examinations and follow-up appointments. - 5\. Rutherford Classification Category 2-6 Subjects with Rutherford Category 2 have gone through a conservative therapy without success. - 6\. Inflow lesion treated prior to target lesion treatment Who Should NOT Join This Trial: - 1\. Rutherford Classification Category 0, 1 - 2\. Patient already enrolled in other investigational (interventional) studies that would interfere with study endpoints - 3\. Inability to tolerate required antithrombotic or antiplatelet therapies. - 4\. Non-dilatable severely calcified lesion. - 5\. Known hypersensitivity/allergy to components of the investigational device - 6\. Un-treated acute or subacute thrombus in the target lesion. - 7\. Life expectancy \< 1 year. - 8\. Pregnancy or female patient with child bearing potential not taking adequate contraceptives or currently lactating. - 9\. Other comorbidities, which in the opinion of the investigator limit longevity or likelihood of compliance with protocol follow up. - 10\. Myocardial infarction or stroke within 30 days prior to index procedure. Always talk to your doctor about whether this trial is right for you.